1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

Galapagos and Janssen part ways following 'therapeutic shift'

 
• By Sukaina Virji

Galapagos, which said in December that its partnership with Janssen Pharmaceutica was "very much alive," now says the companies have agreed to mutually terminate their inflammation alliance and option agreements. "The therapeutic indications of these programs have shifted along the way and moved outside focus areas of Janssen," Galapagos CEO Onno van de Stolpe told Scrip.

Galapagos, which said in December that its partnership with Janssen Pharmaceutica was "very much alive," now says the companies have agreed to mutually terminate their inflammation alliance and option agreements. "The therapeutic indications of these programs have shifted along the way and moved outside focus areas of Janssen," Galapagos CEO Onno van de Stolpe told Scrip.

Among others, all rights to candidate drug GLPG1690, a selective autotaxin inhibitor, have been returned to Galapagos. A first-in-human Phase...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

Wave Aspires To Accelerated Approval In DMD With 48-Week Data

 
• By Joseph Haas

With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.